NCT01601847View on ClinicalTrials.gov

Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 12, 2017

Study Completion Date

March 12, 2017

Conditions
WheezingAllergy
Interventions
DIETARY_SUPPLEMENT

Cholecalciferol

Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity

DRUG

Cholecalciferol

Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity

Trial Locations (5)

10467

Montefiore Medical Center, New York

29425

Medical University of South Carolina, Charleston

44023

Case Western Reserve University, Cleveland

University Hospitals, Cleveland

44109

MetroHealth Medical Center, Cleveland

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Office of Dietary Supplements (ODS)

NIH

lead

Case Western Reserve University

OTHER

NCT01601847 - Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy | Biotech Hunter | Biotech Hunter